BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28872154)

  • 1. Ethnicity and ERG frequency in prostate cancer.
    Sedarsky J; Degon M; Srivastava S; Dobi A
    Nat Rev Urol; 2018 Feb; 15(2):125-131. PubMed ID: 28872154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput differential identification of TMPRSS2-ERG fusion genes in prostate cancer patient urine.
    Lee H; Lee D; Park JH; Song SH; Jeong IG; Kim CS; Searson PC; Lee KH
    Biomaterials; 2017 Aug; 135():23-29. PubMed ID: 28478327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Discriminators of Racial Disparities in Prostate Cancer.
    Ateeq B; Bhatia V; Goel S
    Trends Cancer; 2016 Mar; 2(3):116-120. PubMed ID: 28741531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
    Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R
    Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: Stuck in the middle: interstitial genes in TMPRSS2-ERG fusion.
    Stone L
    Nat Rev Urol; 2018 Jan; 15(1):3. PubMed ID: 29205202
    [No Abstract]   [Full Text] [Related]  

  • 6. Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.
    Juhnke M; Heumann A; Chirico V; Höflmayer D; Menz A; Hinsch A; Hube-Magg C; Kluth M; Lang DS; Möller-Koop C; Sauter G; Simon R; Beyer B; Pompe R; Thederan I; Schlomm T; Luebke AM
    Mol Carcinog; 2017 Sep; 56(9):2135-2145. PubMed ID: 28467610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
    Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
    Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
    Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
    Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
    Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
    Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
    Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H
    Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
    Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
    BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
    Graff RE; Judson G; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
    Prostate; 2017 May; 77(6):647-653. PubMed ID: 28102015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
    Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
    Udager AM; DeMarzo AM; Shi Y; Hicks JL; Cao X; Siddiqui J; Jiang H; Chinnaiyan AM; Mehra R
    Prostate; 2016 Jun; 76(9):845-53. PubMed ID: 27159573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
    BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.
    Sung JY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kang SY; Choi YL; Kwon GY
    J Clin Pathol; 2016 Jul; 69(7):586-92. PubMed ID: 26670747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.